Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy

1Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. doi: 10.3322/caac.21654Siegel RL Miller KD Fuchs HE Jemal A Cancer statistics, 2021 CA Cancer J Clin 2021 71 7 33 10.3322/caac.2165433433946Open DOISearch in Google Scholar

2Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-9. doi: 10.1093/jnci/djp369Broglio KR Berry DA Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 2009 101 1642 9 10.1093/jnci/djp369413723219903805Open DOISearch in Google Scholar

3Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010; 21: 2324-32. doi: 10.1093/annonc/mdq204Soria JC Massard C Le Chevalier T Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010 21 2324 32 10.1093/annonc/mdq20420497965Open DOISearch in Google Scholar

4Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34. doi: 10.1200/JCO.2007.14.5466Reck M von Pawel J Zatloukal P Ramlau R Gorbounova V Hirsh V et al Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 2009 27 1227 34 10.1200/JCO.2007.14.546619188680Open DOISearch in Google Scholar

5Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010; 28: 1958-62. doi: 10.1200/JCO.2009.25.5414Saad ED Katz A Buyse M Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials J Clin Oncol 2010 28 1958 62 10.1200/JCO.2009.25.541420194852Open DOISearch in Google Scholar

6Sundar S, Wu J, Hillaby K, Yap J, Lilford R. A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. Gynecol Oncol 2012; 125: 493-9. doi: 10.1016/j.ygyno.2011.12.420Sundar S Wu J Hillaby K Yap J Lilford R A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer Gynecol Oncol 2012 125 493 9 10.1016/j.ygyno.2011.12.42022155676Open DOISearch in Google Scholar

7Petrelli F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol 2013; 24: 186-92. doi: 10.1093/annonc/mds289Petrelli F Barni S Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer Ann Oncol 2013 24 186 92 10.1093/annonc/mds28922898038Open DOISearch in Google Scholar

8Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS One 2011; 6: e26646. doi: 10.1371/journal.pone.0026646Hotta K Kiura K Fujiwara Y Takigawa N Hisamoto A Ichihara E et al Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review PLoS One 2011 6 e26646 10.1371/journal.pone.0026646321963322114662Open DOISearch in Google Scholar

9Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 1537-41. doi: 10.1093/annonc/mdr487Hayashi H Okamoto I Morita S Taguri M Nakagawa K Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer Ann Oncol 2012 23 1537 41 10.1093/annonc/mdr48722039091Open DOISearch in Google Scholar

10Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer 2013; 14: 261-6. doi: 10.1016/j.cllc.2012.09.006Hayashi H Okamoto I Taguri M Morita S Nakagawa K Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy Clin Lung Cancer 2013 14 261 6 10.1016/j.cllc.2012.09.00623107465Open DOISearch in Google Scholar

11Capewell S, Sudlow MF. Performance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group. Thorax 1990; 45: 951-6. doi: 10.1136/thx.45.12.951Capewell S Sudlow MF Performance and prognosis in patients with lung cancer The Edinburgh Lung Cancer Group. Thorax 1990 45 951 6 10.1136/thx.45.12.9514628452177921Open DOISearch in Google Scholar

12Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010; 5: 620-30. doi: 10.1097/JTO.0b013e3181d2dcd9Kawaguchi T Takada M Kubo A Matsumura A Fukai S Tamura A et al Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC J Thorac Oncol 2010 5 620 30 10.1097/JTO.0b013e3181d2dcd920354456Open DOISearch in Google Scholar

13McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008; 67: 257-62. doi: 10.1017/S0029665108007131McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer Proc Nutr Soc 2008 67 257 62 10.1017/S002966510800713118452641Open DOISearch in Google Scholar

14Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004; 90: 1704-.6. doi: 10.1038/sj.bjc.6601789Forrest LM McMillan DC McArdle CS Angerson WJ Dunlop DJ Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer Br J Cancer 2004 90 1704 6 10.1038/sj.bjc.6601789240973715150622Open DOISearch in Google Scholar

15Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, et al. The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer 2012; 77: 383-8. doi: 10.1016/j.lungcan.2012.04.008Gioulbasanis I Pallis A Vlachostergios PJ Xyrafas A Giannousi Z Perdikouri IE et al The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer Lung Cancer 2012 77 383 8 10.1016/j.lungcan.2012.04.00822551892Open DOISearch in Google Scholar

16Leung EY, Scott HR, McMillan DC. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol 2012; 7: 655-62. doi: 10.1097/JTO.0b013e318244ffe1Leung EY Scott HR McMillan DC Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer J Thorac Oncol 2012 7 655 62 10.1097/JTO.0b013e318244ffe122425914Open DOISearch in Google Scholar

17Umihanic S, Umihanic S, Jamakosmanovic S, Brkic S, Osmic M, Dedic S, et al. Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV. Med Arch 2014; 68: 83-5. doi: 10.5455/ medarh.2014.68.83-85Umihanic S Umihanic S Jamakosmanovic S Brkic S Osmic M Dedic S et al Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV Med Arch 2014 68 83 5 10.5455/medarh.2014.68.83-85427249324937927Open DOISearch in Google Scholar

18Jiang AG, Chen HL, Lu HY. Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2015; 141: 563-8. doi: 10.1007/s00432-014-1839-4Jiang AG Chen HL Lu HY Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer J Cancer Res Clin Oncol 2015 141 563 8 10.1007/s00432-014-1839-425257958Open DOISearch in Google Scholar

19Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, et al. Prognosis in advanced lung cancer – a prospective study examining key clinicopathological factors. Lung Cancer 2015; 88: 304-9. doi: 10.1016/j.lungcan.2015.03.020Simmons CP Koinis F Fallon MT Fearon KC Bowden J Solheim TS et al Prognosis in advanced lung cancer – a prospective study examining key clinicopathological factors Lung Cancer 2015 88 304 9 10.1016/j.lungcan.2015.03.02025870155Open DOISearch in Google Scholar

20Imai H, Kishikawa T, Minemura H, Yamada Y, Ibe T, Yamaguchi O, et al. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab mono-therapy for non-small cell lung cancer. Cancer Med 2021; 10: 6971-84. doi: 10.1002/cam4.4220Imai H Kishikawa T Minemura H Yamada Y Ibe T Yamaguchi O et al Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab mono-therapy for non-small cell lung cancer Cancer Med 2021 10 6971 84 10.1002/cam4.4220852516534414673Open DOISearch in Google Scholar

21Imai H, Kaira K, Minato K. Clinical significance of post-progression survival in lung cancer. Thorac Cancer 2017; 8:379-86. doi 10.1111/1759-7714.12463Imai H Kaira K Minato K Clinical significance of post-progression survival in lung cancer Thorac Cancer 2017 8379 86 10.1111/1759-7714.12463558245928627767Open DOISearch in Google Scholar

22Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008; 3: 917-28. doi: 10.1097/ JTO.0b013e318180270bGovindan R Bogart J Vokes EE Locally advanced non-small cell lung cancer: the past, present, and future J Thorac Oncol 2008 3 917 28 10.1097/JTO.0b013e318180270b18670313Open DOISearch in Google Scholar

23Sause W, Kolesar P, Taylor SI, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 358-64. doi: 10.1378/chest.117.2.358Sause W Kolesar P Taylor SI Johnson D Livingston R Komaki R et al Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest 2000 117 358 64 10.1378/chest.117.2.35810669675Open DOISearch in Google Scholar

24Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-90. doi: 10.1200/JCO.2009.26.2543Auperin A Le Pechoux C Rolland E Curran WJ Furuse K Fournel P et al Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 2010 28 2181 90 10.1200/JCO.2009.26.254320351327Open DOISearch in Google Scholar

25Vokes EE, Herndon JE, 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-704. doi: 10.1200/JCO.2006.07.3569Vokes EE Herndon JE 2nd Kelley MJ Cicchetti MG Ramnath N Neill H et al Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B J Clin Oncol 2007 25 1698 704 10.1200/JCO.2006.07.356917404369Open DOISearch in Google Scholar

26Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056/NEJMoa1709937Antonia SJ Villegas A Daniel D Vicente D Murakami S Hui R et al Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer N Engl J Med 2017 377 1919 29 10.1056/NEJMoa170993728885881Open DOISearch in Google Scholar

27Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-50. doi: 10.1056/NEJMoa1809697Antonia SJ Villegas A Daniel D Vicente D Murakami S Hui R et al Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC N Engl J Med 2018 379 2342 50 10.1056/NEJMoa180969730280658Open DOISearch in Google Scholar

28Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010; 40: 107-11. doi: 10.1093/jjco/hyp167Niibe Y Hayakawa K Oligometastases and oligo-recurrence: the new era of cancer therapy Jpn J Clin Oncol 2010 40 107 11 10.1093/jjco/hyp167281354520047860Open DOISearch in Google Scholar

29Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: 10.1016/j.ejca.2008.10.026Eisenhauer EA Therasse P Bogaerts J Schwartz LH Sargent D Ford R et al New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 228 47 10.1016/j.ejca.2008.10.02619097774Open DOISearch in Google Scholar

30Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006; 7: 741-6. doi: 10.1016/S1470-2045(06)70800-2Johnson KR Ringland C Stokes BJ Anthony DM Freemantle N Irs A et al Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis Lancet Oncol 2006 7 741 6 10.1016/S1470-2045(06)70800-216945769Open DOISearch in Google Scholar

31Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 311-7. doi: 10.1097/JTO.0b013e3181989bd2Hotta K Fujiwara Y Matsuo K Kiura K Takigawa N Tabata M et al Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer J Thorac Oncol 2009 4 311 7 10.1097/JTO.0b013e3181989bd219190515Open DOISearch in Google Scholar

32Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 2006; 25: 183-203. doi: 10.1002/ sim.2319Weir CJ Walley RJ Statistical evaluation of biomarkers as surrogate endpoints: a literature review Stat Med 2006 25 183 203 10.1002/sim.231916252272Open DOISearch in Google Scholar

33Fleischer F, Gaschler-Markefski B, Bluhmki E. A statistical model for the dependence between progression-free survival and overall survival. Stat Med 2009; 28: 2669-86. doi: 10.1002/sim.3637Fleischer F Gaschler-Markefski B Bluhmki E A statistical model for the dependence between progression-free survival and overall survival Stat Med 2009 28 2669 86 10.1002/sim.363719579225Open DOISearch in Google Scholar

34Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011; 117: 1262-71. doi: 10.1002/cncr.25526Foster NR Qi Y Shi Q Krook JE Kugler JW Jett JR et al Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials Cancer 2011 117 1262 71 10.1002/cncr.25526302526720960500Open DOISearch in Google Scholar

35Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I, et al. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2012; 39: 9-28. doi: 10.1183/09031936.00190310Berghmans T Pasleau F Paesmans M Bonduelle Y Cadranel J Cs Toth I et al Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations Eur Respir J 2012 39 9 28 10.1183/09031936.0019031021737547Open DOISearch in Google Scholar

36Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, et al. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 2009; 4: 994-1001. doi: 10.1097/JTO.0b013e3181a94a2fTsujino K Kawaguchi T Kubo A Aono N Nakao K Koh Y et al Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib J Thorac Oncol 2009 4 994 1001 10.1097/JTO.0b013e3181a94a2f19633474Open DOISearch in Google Scholar

37Li X, Liu S, Gu H, Wang D. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. J Cancer Res Clin Oncol 2012; 138: 1963-9. doi: 10.1007/s00432-012-1278-zLi X Liu S Gu H Wang D Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib J Cancer Res Clin Oncol 2012 138 1963 9 10.1007/s00432-012-1278-z22763646Open DOISearch in Google Scholar

38Imai H, Onozato R, Kaira K, Kawashima S, Masubuchi K, Nagashima T, et al. Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival. Thorac Cancer 2021; 12: 2740-8. doi: 10.1111/1759-7714.14119Imai H Onozato R Kaira K Kawashima S Masubuchi K Nagashima T et al Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival Thorac Cancer 2021 12 2740 8 10.1111/1759-7714.14119852081334477313Open DOISearch in Google Scholar

39Imai H, Takahashi T, Mori K, Ono A, Akamatsu H, Shukuya T, et al. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. Neoplasma 2014; 61: 233-40. doi: 10.4149/neo_2014_030Imai H Takahashi T Mori K Ono A Akamatsu H Shukuya T et al Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer Neoplasma 2014 61 233 40 10.4149/neo_2014_03024299320Open DOISearch in Google Scholar

40Imai H, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, et al. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. Med Oncol 2014; 31: 88. doi: 10.1007/s12032-014-0088-3Imai H Mori K Ono A Akamatsu H Taira T Kenmotsu H et al Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy Med Oncol 2014 31 88 10.1007/s12032-014-0088-324961467Open DOISearch in Google Scholar

41Imai H, Kaira K, Mori K, Kotake M, Mitani M, Kawashima N, et al. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Thorac Cancer 2019; 10: 2200-8. doi: 10.1111/1759-7714.13193Imai H Kaira K Mori K Kotake M Mitani M Kawashima N et al Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors Thorac Cancer 2019 10 2200 8 10.1111/1759-7714.13193688543531595714Open DOISearch in Google Scholar

42Jiang T, Cheng R, Zhang G, Su C, Zhao C, Li X, et al. Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study. Clin Lung Cancer 2017; 18: 631-9. doi: 10.1016/j.cllc.2017.04.015Jiang T Cheng R Zhang G Su C Zhao C Li X et al Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study Clin Lung Cancer 2017 18 631 9 10.1016/j.cllc.2017.04.01528549835Open DOISearch in Google Scholar

43Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, et al. Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients. Clin Lung Cancer 2019; 20: e601-8. doi: 10.1016/j.cllc.2019.06.020Sridhar S Paz-Ares L Liu H Shen K Morehouse C Rizvi N et al Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients Clin Lung Cancer 2019 20 e601 8 10.1016/j.cllc.2019.06.02031327642Open DOISearch in Google Scholar

44Choi MG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, et al. Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study. Transl Lung Cancer Res 2021; 10: 2551-61. doi: 10.21037/tlcr-21-206Choi MG Choi CM Lee DH Kim SW Yoon S Kim WS et al Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study Transl Lung Cancer Res 2021 10 2551 61 10.21037/tlcr-21-206826433034295661Open DOISearch in Google Scholar